Kyle D. Kuvalanka has served as Aktis Oncology's Chief Financial Officer since November 2025. He was previously Chief Financial Officer and Chief Business Officer of ROME Therapeutics, and earlier served as Chief Financial Officer and Chief Operating Officer of Goldfinch Bio, as well as Chief Operating Officer and principal financial officer of Syros Pharmaceuticals and Chief Business Officer of Blueprint Medicines. He holds a BA from Wesleyan University and an MBA from The Wharton School of the University of Pennsylvania.